Hsbc Holdings PLC Aptinyx Inc. Transaction History

Hsbc Holdings PLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$0.38 - $2.58 $1,452 - $9,863	-3,823 Reduced 9.33%	37,152 $20,000
Q2 2021 Aug 13, 2021	BUY	$2.39 - $3.5 $71 - $105	30 Added 0.07%	40,975 $115,000
Q1 2021 May 14, 2021	SELL	$2.86 - $4.33 $2,305 - $3,489	-806 Reduced 1.93%	40,945 $122,000
Q4 2020 Feb 12, 2021	SELL	$2.93 - $4.3 $17,656 - $25,911	-6,026 Reduced 12.61%	41,751 $144,000
Q3 2020 Nov 12, 2020	SELL	$3.05 - $4.99 $30 - $49	-10 Reduced 0.02%	47,777 $161,000
Q2 2020 Aug 14, 2020	BUY	$1.99 - $4.4 $19 - $44	10 Added 0.02%	47,787 $199,000
Q4 2019 Feb 14, 2020	SELL	$2.84 - $4.25 $135,686 - $203,052	-47,777 Reduced 50.0%	47,777 $162,000
Q3 2019 Nov 14, 2019	BUY	$3.0 - $4.08 $286,662 - $389,860	95,554 New	95,554 $333,000

Ticker APTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,715,696
Description
Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic pe...

Get notified when there are updates to the investment portfolio of Hsbc Holdings PLC, based on Form 13F filings with the SEC.

Stay updated on Hsbc Holdings PLC with notifications on news.